Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADLNASDAQ:CRVSNASDAQ:CYCCNASDAQ:DSGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$5.53-5.5%$5.19$3.79▼$14.60$273.06M-0.921.46 million shs1.10 million shsCRVSCorvus Pharmaceuticals$3.80$3.40$1.75▼$10.00$259.04M0.67736,845 shs509,024 shsCYCCCyclacel Pharmaceuticals$1.65+3.1%$3.41$1.36▼$41.12$25.39M0.52111,966 shs229,083 shsDSGNDesign Therapeutics$3.73-7.0%$3.68$2.60▼$7.77$227.64M1.77185,371 shs69,291 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics-5.47%+1.84%+12.63%-38.42%-37.09%CRVSCorvus Pharmaceuticals0.00%+8.88%+5.85%-5.94%+80.95%CYCCCyclacel Pharmaceuticals+3.06%+13.72%-60.08%-68.91%-94.97%DSGNDesign Therapeutics-6.98%-2.10%-23.25%-23.25%-3.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics1.9222 of 5 stars3.51.00.00.02.31.70.6CRVSCorvus Pharmaceuticals2.1745 of 5 stars3.51.00.00.02.32.50.6CYCCCyclacel Pharmaceuticals1.4245 of 5 stars0.05.00.00.03.61.70.0DSGNDesign Therapeutics0.5037 of 5 stars1.00.00.00.02.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.00Buy$21.00279.75% UpsideCRVSCorvus Pharmaceuticals 3.00Buy$15.00294.74% UpsideCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/ADSGNDesign Therapeutics 2.00Hold$4.007.24% UpsideCurrent Analyst Ratings BreakdownLatest CYCC, DSGN, CRVS, and CADL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025CRVSCorvus PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$12.00 ➝ $11.005/9/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/26/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$14.00 ➝ $15.003/26/2025CRVSCorvus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/14/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,308.91N/AN/A$0.44 per share12.57CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.79 per shareN/ACYCCCyclacel Pharmaceuticals$14K1,813.55N/AN/A$0.57 per share2.89DSGNDesign TherapeuticsN/AN/AN/AN/A$4.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$37.94M-$1.34N/AN/AN/AN/A-629.29%-173.39%8/12/2025 (Estimated)CRVSCorvus Pharmaceuticals-$27.03M-$0.98N/AN/AN/AN/A-70.71%-45.90%8/12/2025 (Estimated)CYCCCyclacel Pharmaceuticals-$22.56M-$56.00N/A∞N/A-18,150.00%-1,901.11%-188.23%6/3/2025 (Estimated)DSGNDesign Therapeutics-$66.86M-$0.99N/AN/AN/AN/A-18.01%-17.38%8/4/2025 (Estimated)Latest CYCC, DSGN, CRVS, and CADL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q1 2025CYCCCyclacel Pharmaceuticals-$0.29-$0.33-$0.04N/A$0.03 millionN/A5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/8/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.13-$0.13N/A-$0.13N/AN/A4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$4.64-$5.28-$0.64-$0.33$0.01 million$0.01 million3/25/2025Q4 2024CRVSCorvus Pharmaceuticals-$0.12-$0.18-$0.06-$0.18N/AN/A3/13/2025Q4 2024CADLCandel Therapeutics-$0.23-$0.40-$0.17-$0.40N/AN/A3/10/2025Q4 2024DSGNDesign Therapeutics-$0.28-$0.24+$0.04-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals$0.159.10%N/AN/A N/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/ALatest CYCC, DSGN, CRVS, and CADL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$2.404/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel TherapeuticsN/A1.181.18CRVSCorvus PharmaceuticalsN/A0.920.92CYCCCyclacel PharmaceuticalsN/A0.770.77DSGNDesign TherapeuticsN/A34.6134.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%CRVSCorvus Pharmaceuticals46.64%CYCCCyclacel Pharmaceuticals23.58%DSGNDesign Therapeutics56.64%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%CRVSCorvus Pharmaceuticals31.30%CYCCCyclacel Pharmaceuticals68.00%DSGNDesign Therapeutics31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6050.10 million18.97 millionOptionableCRVSCorvus Pharmaceuticals3068.17 million44.15 millionOptionableCYCCCyclacel Pharmaceuticals1415.40 million4.78 millionOptionableDSGNDesign Therapeutics4056.77 million38.96 millionOptionableCYCC, DSGN, CRVS, and CADL HeadlinesRecent News About These CompaniesDesign Therapeutics to Participate in 2025 Jefferies Global Healthcare ConferenceMay 28 at 8:00 AM | globenewswire.comPoint72 Asset Management L.P. Buys 256,010 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)May 21, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Cuts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)May 21, 2025 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LPMay 18, 2025 | marketbeat.comMPM Bioimpact LLC Purchases New Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)May 16, 2025 | marketbeat.comBridgeway Capital Management LLC Has $792,000 Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)May 14, 2025 | marketbeat.comDesign Therapeutics to Participate in 2025 RBC Capital Markets Healthcare ConferenceMay 13, 2025 | globenewswire.comQ2 EPS Forecast for Design Therapeutics Reduced by AnalystMay 13, 2025 | marketbeat.com776,082 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Bought by Driehaus Capital Management LLCMay 12, 2025 | marketbeat.comDesign Therapeutics (DSGN) to Release Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comDesign Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comDesign Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025May 3, 2025 | nasdaq.comDesign Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal DystrophyMay 1, 2025 | globenewswire.comWhy Design Therapeutics, Inc.’s (DSGN) Stock Is Down 5.42%April 25, 2025 | aaii.comDesign Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025April 22, 2025 | nasdaq.comDesign Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025April 21, 2025 | globenewswire.comDesign Therapeutics appoints Chris Storgard as CMOApril 19, 2025 | markets.businessinsider.comDesign Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical OfficerApril 17, 2025 | globenewswire.comBright Peak Therapeutics Appoints John Schmid to its Board of DirectorsApril 17, 2025 | markets.businessinsider.comDesign Therapeutics (DSGN) Upgraded to Buy: Here's WhyMarch 12, 2025 | zacks.comWall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?March 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYCC, DSGN, CRVS, and CADL Company DescriptionsCandel Therapeutics NASDAQ:CADL$5.53 -0.32 (-5.47%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$5.51 -0.02 (-0.36%) As of 05/30/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Corvus Pharmaceuticals NASDAQ:CRVS$3.80 0.00 (0.00%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.79 -0.01 (-0.26%) As of 05/30/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Cyclacel Pharmaceuticals NASDAQ:CYCC$1.65 +0.05 (+3.06%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.70 +0.05 (+3.09%) As of 05/30/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Design Therapeutics NASDAQ:DSGN$3.73 -0.28 (-6.98%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.74 +0.02 (+0.40%) As of 05/30/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
